<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02221102</url>
  </required_header>
  <id_info>
    <org_study_id>Xijing-Edoxaban</org_study_id>
    <nct_id>NCT02221102</nct_id>
  </id_info>
  <brief_title>Edoxaban for TIA and Acute Minor Stroke</brief_title>
  <official_title>Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent
      stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and
      slightly increase the risk of intracerebral hemorrhage. Recently, edoxaban, a new oral
      anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying
      significantly less risk of intracranial hemorrhage.

      This trial is a randomized, double-blind, multicenter, controlled clinical trial in China.
      The investigators will assess the hypothesis that a 30-days edoxaban regimen is superior to
      aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular
      event.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with new stroke (ischemic or hemorrhage)</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with new clinical vascular events (ischemic stroke/hemorrhagic stroke/TIA/myocardial infarction/vascular death)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS score changes (continuous) and dichotomized at percentage with score 0 to 2 versus 3 to 6</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NIHSS scores</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>moderate to severe bleeding events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events/severe adverse events reported by the investigators</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Ischemia</condition>
  <condition>Stroke</condition>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>edoxaban 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>edoxaban 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>non-steroidal anti-inflammatory drugs</description>
    <arm_group_label>aspirin</arm_group_label>
    <other_name>Acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edoxaban</intervention_name>
    <description>orally active direct factor Xa inhibitor</description>
    <arm_group_label>edoxaban 30mg</arm_group_label>
    <arm_group_label>edoxaban 60mg</arm_group_label>
    <other_name>DU176b</other_name>
    <other_name>LIXIANA TABLETS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_label>edoxaban 30mg</arm_group_label>
    <arm_group_label>edoxaban 60mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (male or female ≥18 years old)

          -  Acute nondisabling ischemic stroke (NIHSS ≤3 at the time of randomization) that can be
             treated with study drug within 24 hours of symptoms onset. Symptom onset is defined by
             the &quot;last see normal&quot; principle

          -  TIA (neurologic deficit attributed to focal brain ischemia, with resolution of the
             deficit within 24 hours of symptom onset), that can be treated with investigational
             medication within 24 hours of symptoms onset. Symptom onset is defined by the &quot;last
             see normal&quot; principle

          -  Informed consent signed

        Exclusion Criteria:

          -  Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor,
             abscess or other major nonischemic brain disease, on baseline head CT or MRI scan

          -  mRS score &gt;2 at randomization (premorbid historical assessment)

          -  NIHSS ≥4 at randomization

          -  Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves,
             deep venous thrombosis, pulmonary embolism or known hypercoagulable state)

          -  Contraindication to investigational medications

          -  Thrombolysis for ischemic stroke within preceding 7 days

          -  History of intracranial hemorrhage

          -  Current treatment (last dose given within 10 days before randomization) with heparin
             therapy or oral anticoagulation

          -  Gastrointestinal bleed or major surgery within 3 months

          -  Planned or likely revascularization (any angioplasty or vascular surgery) within the
             next 3 months

          -  TIA or minor stroke induced by angiography or surgery

          -  Severe noncardiovascular comorbidity with life expectancy &lt;3 months

          -  Women of childbearing age not practicing reliable contraception who do not have a
             documented negative pregnancy test result

          -  Severe renal failure, defined as Glomerular Filtration Rate (GFR) &lt;30 ml/min -Severe
             hepatic insufficiency (Child-Pugh score B to C)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zhao, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing hostipal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuedong Liu</last_name>
    <phone>+86 029 84775055</phone>
    <email>liuxued@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Yang, M.D. Ph.D.</last_name>
      <phone>+86 029 84773214</phone>
      <email>fyangx@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Gang Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>edoxaban</keyword>
  <keyword>aspirin</keyword>
  <keyword>new oral anticoagulant</keyword>
  <keyword>TIA</keyword>
  <keyword>acute minor ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

